ClinicalTrials.gg
RecruitingNCT07353021Updated Nov 12, 2026

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

An interventional study of Active dermal patch and Placebo patch in Anxiety and Sleep, sponsored by Natural Immune Systems Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal for this clinical trial is to compare an active biofield non-transdermal skin patch to a placebo patch in people who frequently experience anxiety.

Read the detailed description

The goal for this clinical trial is to document effects of a photobiomodulating non-transdermal patch compared to a placebo patch, in a randomized double-blind placebo-controlled design.

Data on stress and anxiety levels will be collected using the GAD and OASIS questionnaires as well as the Warwick-Edinburgh Mental Wellbeing Scales collected. The data collected will show whether the daily use of the patch leads to a change in general self-reported stress and anxiety levels. Data on energy levels will be collected using a Wellness questionnaire. Data on sleep quality will be collected using the Leeds sleep evaluation questionnaire, to document whether using the active patch impacts self-reported sleep.

02

Conditions studied

  • Anxiety
  • Sleep

Browse trials for

Keywords

  • Sleep
  • Stress
  • Anxiety
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 40 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults of all genders;
  • Age 18-75 years (inclusive);
  • between 18.0 and 34.9 (inclusive)
  • Experiencing intermittent episodes of anxiety on a regular basis, leading to either avoiding specific situations, or experiencing stress both in anticipation of, and during such situations.

    • Specific situations that occur regularly that cause anxiety, for example:

      • Performing specific tasks at work or at home;
      • Inter-personal conflicts at work or at home;
      • Driving or commuting;
      • Fearful and worrying about one's own situation (such as paying bills);
      • Worrying about ongoing problems experienced by others.

Exclusion criteria

Exclusion Criteria:

  • Cancer during past 12 months;
  • Chemotherapy during past 12 months;
  • Currently taking anxiolytic, hypnotic, or anti-depressant prescription medication;
  • Currently taking nutritional supplements judged by the study coordinator to negate or camouflage the effects of the test product;
  • Participation in another clinical trial study during this trial, involving an product or lifestyle change;
  • Serious active illness within past 6 months;
  • People who are pregnant, nursing, or trying to become pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants will use an active biofield patch daily for 4 weeks. The active biofield patch will look identical to a placebo patch, and will be blinded.

    Device: Active dermal patch

  • Experimental
    Group 2

    Participants will use a placebo patch daily for 4 weeks. The placebo patch will look identical to an active patch, and will be blinded.

    Device: Placebo patch

Interventions

  • DeviceActive dermal patch

    Non-transdermal patch

  • DevicePlacebo patch

    Non-transdermal patch

06

What researchers measure

Primary outcomes

  1. General Anxiety Disorder 7 (GAD 7) Questionnaire

    Change from baseline in anxiety score using the General Anxiety Disorder 7-item. The General Anxiety Disorder-7 scale evaluates anxiety severity using scores ranging from 0-21, where higher scores indicate higher anxiety severity.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

Secondary outcomes

  1. Overal Anxiety Severity and Impairment Scale (OASIS) Questionnaire

    Change from baseline in Overall Anxiety Severity and Impairment Scale (OASIS) score. The Overall Anxiety Severity and Impairment scale evaluates anxiety and impact on daily living in participants with a score between 0 and 25, where higher scores indicate higher anxiety severity and impact on daily living.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

Other outcomes

  1. Warwick-Edinburgh Mental Wellbeing Scale

    Changes from baseline in mental wellbeing using the Warwick-Edinburgh Mental Wellbeing scale. The Warwick-Edinburgh Mental Wellbeing scale evaluates self reported happiness and satisfaction as well as psychological functioning, good relationships with others, and self realization.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  2. Wellness Questionnaire

    Change from baseline in wellness evaluated using a Wellness questionnaire. The Wellness questionnaire consists of 30 questions, generating scores for physical, mental functioning, emotional wellbeing, stress, social functioning, sleep, and energy/vitality, where higher scores reflect better wellness.

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks

  3. Leeds Sleep Questionnaire

    Changes from baseline in sleep quality. The Leeds Sleep Evaluation Questionnaire is a 10 item linear-log scale based on questions across several domains of sleep, where higher scores reflect better sleep quality

    Time frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 8 months is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jan 2026 → Oct 2026, primary completion Dec 2026 → Jun 2027 and completion Mar 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 20, 2026
StartActual
Oct 23, 2026was Jan 2026
Primary completionEst.
Jun 2027was Dec 2026
CompletionEst.
Sep 2027was Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
NIS Labs is now Recruiting
Nov 12, 2026
Start date
Jan 2026→Oct 23, 2026 (actual)
Nov 12, 2026
Primary completion
Dec 2026→Jun 2027
Nov 12, 2026
Study completion
Mar 2027→Sep 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    NIS Labs is now Recruiting
    Start date Jan 2026→Oct 23, 2026 (now actual)
    Primary completion Dec 2026→Jun 2027
    Study completion Mar 2027→Sep 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07353021
Lead sponsor
Natural Immune Systems Inc
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Oct 23, 2026
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Gitte S Jensen, PhD
Contact
Gitte@nislabs.com
541 882 0112
Alex Cruickshank
Contact
Alex@nislabs.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion